Innate lymphoid cells: Major players in inflammatory diseases

Nature Reviews Immunology

Volumn 17, Issue 11, 2017, Pages 665-678

  Ebbo, Mikaël ^a,b   Crinier, Adeline ^a   Vély, Frédéric ^a,b   Vivier, Eric ^a,b  

^a CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

^b TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ASTHMA; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; CELL INTERACTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RHINOSINUSITIS; EOSINOPHILIC GASTROINTESTINAL DISORDER; HOMEOSTASIS; HUMAN; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; LUNG FIBROSIS; LYMPHOID CELL; NONHUMAN; NOSE POLYP; PRIORITY JOURNAL; PSORIASIS; RESPIRATORY TRACT INFLAMMATION; REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VIRUS INFECTION; ANIMAL; ANTIBODY SPECIFICITY; CLASSIFICATION; DISEASE PREDISPOSITION; IMMUNOLOGY; INNATE IMMUNITY; LYMPHOCYTE SUBPOPULATION; METABOLISM;

ANIMALS; DISEASE SUSCEPTIBILITY; HUMANS; IMMUNITY, INNATE; INFLAMMATION; LYMPHOCYTE SUBSETS; ORGAN SPECIFICITY;

EID: 85032359621     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri.2017.86     Document Type: Review

References (144)

1. Cella, M. et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 457, 722-725 (2009).
2. + cell subsets from Id2-dependent precursors. J. Exp. Med. 207, 273-280 (2010).
3. + lymphoid cells. Nature 463, 540-544 (2010).
4. Neill, D. R. et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 464, 1367-1370 (2010).
5. + cell populations in gut and skin. Nat. Immunol. 10, 75-82 (2009).
6. + cells. Nat. Immunol. 10, 83-91 (2009).
7. + natural killer-like cells. Nat. Immunol. 10, 66-74 (2009).
8. Price, A. E. et al. Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc. Natl Acad. Sci. USA 107, 11489-11494 (2010).
9. Spits, H. et al. Innate lymphoid cells-a proposal for uniform nomenclature. Nat. Rev. Immunol. 13, 145-149 (2013).
10. +ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures. Nat. Commun. 6, 8280 (2015).
11. Kirchberger, S. et al. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J. Exp. Med. 210, 917-931 (2013).
12. van Beek, J. J. P., Martens, A. W. J., Bakdash, G. & de Vries, I. J. M. Innate lymphoid cells in tumor immunity. Biomedicines 4, E7 (2015).
13. Dadi, S. et al. Cancer immunosurveillance by tissue- resident innate lymphoid cells and innate-like T cells. Cell 164, 365-377 (2016).
14. Dadi, S. & Li, M. O. Tissue-resident lymphocytes: sentinel of the transformed tissue. J. Immunother. Cancer 5, 41 (2017).
15. Croxatto, D. et al. Group 3 innate lymphoid cells regulate neutrophil migration and function in human decidua. Mucosal Immunol. 9, 1372-1383 (2016).
16. Vacca, P. et al. NK cells and other innate lymphoid cells in hematopoietic stem cell transplantation. Front. Immunol. 7, 188 (2016).
17. Morita, H. et al. An interleukin-33-Mast cell- interleukin-2 axis suppresses papain-induced allergic inflammation by promoting regulatory T cell numbers. Immunity 43, 175-186 (2015).
18. Bartemes, K. R., Kephart, G. M., Fox, S. J. & Kita, H. Enhanced innate type 2 immune response in peripheral blood from patients with asthma. J. Allergy Clin. Immunol. 134, 671-678.e4 (2014).
19. Smith, S. G. et al. Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. J. Allergy Clin. Immunol. 137, 75-86.e8 (2016).
20. Christianson, C. A. et al. Persistence of asthma requires multiple feedback circuits involving type 2 innate lymphoid cells and IL-33. J. Allergy Clin. Immunol. 136, 59-68.e14 (2015).
21. Liu, T. et al. Type 2 innate lymphoid cells: a novel biomarker of eosinophilic airway inflammation in patients with mild to moderate asthma. Respir. Med. 109, 1391-1396 (2015).
22. Kabata, H. et al. Thymic stromal lymphopoietin induces corticosteroid resistance in natural helper cells during airway inflammation. Nat. Commun. 4, 2675 (2013).
23. Halim, T. Y. F., Krauss, R. H., Sun, A. C. & Takei, F. Lung natural helper cells are a critical source of Th2 cell-type cytokines in protease allergen-induced airway inflammation. Immunity 36, 451-463 (2012).
24. Halim, T. Y. F. et al. Group 2 innate lymphoid cells are critical for the initiation of adaptive T helper 2 cell- mediated allergic lung inflammation. Immunity 40, 425-435 (2014).
25. Doherty, T. A. et al. STAT6 regulates natural helper cell proliferation during lung inflammation initiated by Alternaria. Am. J. Physiol. Lung Cell. Mol. Physiol. 303, L577-L588 (2012).
26. Chang, Y.-J. et al. Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat. Immunol. 12, 631-638 (2011).
27. Van Dyken, S. J. et al. Chitin activates parallel immune modules that direct distinct inflammatory responses via innate lymphoid type 2 and γδ T cells. Immunity 40, 414-424 (2014).
28. Stier, M. T. et al. Respiratory syncytial virus infection activates IL-13-producing group 2 innate lymphoid cells through thymic stromal lymphopoietin. J. Allergy Clin. Immunol. 138, 814-824.e11 (2016).
29. Lee, H.-C. et al. Thymic stromal lymphopoietin is induced by respiratory syncytial virus-infected airway epithelial cells and promotes a type 2 response to infection. J. Allergy Clin. Immunol. 130, 1187-1196. e5 (2012).
30. Barlow, J. L. et al. Innate IL-13-producing nuocytes arise during allergic lung inflammation and contribute to airways hyperreactivity. J. Allergy Clin. Immunol. 129, 191-198.e1-4 (2012).
31. Martinez-Gonzalez, I. et al. Allergen-experienced group 2 innate lymphoid cells acquire memory-like properties and enhance allergic lung inflammation. Immunity 45, 198-208 (2016).
32. Martinez-Gonzalez, I., Mathä, L., Steer, C. A. & Takei, F. Immunological memory of group 2 innate lymphoid cells. Trends Immunol. 38, 423-431 (2017).
33. de Kleer, I. M. et al. Perinatal activation of the interleukin-33 pathway promotes type 2 immunity in the developing lung. Immunity 45, 1285-1298 (2016).
34. Steer, C. A. et al. Group 2 innate lymphoid cell activation in the neonatal lung drives type 2 immunity and allergen sensitization. J. Allergy Clin. Immunol. http://dx.doi.org/10.1016/j.jaci.2016.12.984 (2017).
35. Saluzzo, S. et al. First-breath-induced type 2 pathways shape the lung immune environment. Cell Rep. 18, 1893-1905 (2017).
36. Moffatt, M. F. et al. A large-scale, consortium-based genomewide association study of asthma. N. Engl. J. Med. 363, 1211-1221 (2010).
37. Torgerson, D. G. et al. Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations. Nat. Genet. 43, 887-892 (2011).
38. Savenije, O. E. M. et al. Interleukin-1 receptor-like 1 polymorphisms are associated with serum IL1RL1-a, eosinophils, and asthma in childhood. J. Allergy Clin. Immunol. 127, 750-756.e1-5 (2011).
39. Saravia, J. et al. Respiratory syncytial virus disease is mediated by age-variable IL-33. PLoS Pathog. 11, e1005217 (2015).
40. Hong, J. Y. et al. Neonatal rhinovirus induces mucous metaplasia and airways hyperresponsiveness through IL-25 and type 2 innate lymphoid cells. J. Allergy Clin. Immunol. 134, 429-439 (2014).
41. Sugita, K. et al. Type 2 innate lymphoid cells disrupt bronchial epithelial barrier integrity by targeting tight junctions via IL-13 in asthma. J. Allergy Clin. Immunol. http://dx.doi.org/2017. 10.1016/j.jaci.2017.02.038 (2017).
42. Motomura, Y. et al. Basophil-derived interleukin-4 controls the function of natural helper cells, a member of ILC2s, in lung inflammation. Immunity 40, 758-771 (2014).
43. Maazi, H. et al. ICOS:ICOS-ligand interaction is required for type 2 innate lymphoid cell function, homeostasis, and induction of airway hyperreactivity. Immunity 42, 538-551 (2015).
44. Harvima, I. T. et al. Molecular targets on mast cells and basophils for novel therapies. J. Allergy Clin. Immunol. 134, 530-544 (2014).
45. H2 cells. J. Allergy Clin. Immunol. 133, 1184-1194 (2014).
46. 2 regulates human type 2 innate lymphoid cell chemotaxis. J. Allergy Clin. Immunol. 133, 899-901.e3 (2014).
47. H2 cytokine production. J. Allergy Clin. Immunol. 132, 205-213 (2013).
48. Barnig, C. et al. Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma. Sci. Transl. Med. 5, 174ra26 (2013).
49. + T cells cooperate to mediate type 2 immune response in mice. Allergy 69, 1300-1307 (2014).
50. + Th2 cell responses. J. Immunol. 192, 2442-2448 (2014).
51. + T cells potentiates type 2 immunity and promotes parasitic helminth expulsion. Immunity 41, 283-295 (2014).
52. H2 cell responses. Nat. Immunol. 17, 57-64 (2016).
53. Gold, M. J. et al. Group 2 innate lymphoid cells facilitate sensitization to local, but not systemic, TH2-inducing allergen exposures. J. Allergy Clin. Immunol. 133, 1142-1148 (2014).
54. Van Dyken, S. J. et al. A tissue checkpoint regulates type 2 immunity. Nat. Immunol. 17, 1381-1387 (2016).
55. Kim, H. Y. et al. Interleukin-17-producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity. Nat. Med. 20, 54-61 (2014).
56. Everaere, L. et al. Innate lymphoid cells contribute to allergic airway disease exacerbation by obesity. J. Allergy Clin. Immunol. 138, 1309-1318.e11 (2016).
57. Mjösberg, J. M. et al. Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat. Immunol. 12, 1055-1062 (2011).
58. Bal, S. M. et al. IL-1β, IL-4 and IL-12 control the fate of group 2 innate lymphoid cells in human airway inflammation in the lungs. Nat. Immunol. 17, 636-645 (2016).
59. Lao-Araya, M., Steveling, E., Scadding, G. W., Durham, S. R. & Shamji, M. H. Seasonal increases in peripheral innate lymphoid type 2 cells are inhibited by subcutaneous grass pollen immunotherapy. J. Allergy Clin. Immunol. 134, 1193-1195.e4 (2014).
60. Fan, D.-C. et al. Suppression of immunotherapy on group 2 innate lymphoid cells in allergic rhinitis. Chin. Med. J. 129, 2824-2828 (2016).
61. Kearley, J. et al. Cigarette smoke silences innate lymphoid cell function and facilitates an exacerbated type I interleukin-33-dependent response to infection. Immunity 42, 566-579 (2015).
62. Silver, J. S. et al. Inflammatory triggers associated with exacerbations of COPD orchestrate plasticity of group 2 innate lymphoid cells in the lungs. Nat. Immunol. 17, 626-635 (2016).
63. Ohne, Y. et al. IL-1 is a critical regulator of group 2 innate lymphoid cell function and plasticity. Nat. Immunol. 17, 646-655 (2016).
64. Li, D. et al. IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice. J. Allergy Clin. Immunol. 134, 1422-1432.e11 (2014).
65. Hams, E. et al. IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis. Proc. Natl Acad. Sci. USA 111, 367-372 (2014).
66. Wohlfahrt, T. et al. Type 2 innate lymphoid cell counts are increased in patients with systemic sclerosis and correlate with the extent of fibrosis. Ann. Rheum. Dis. 75, 623-626 (2016).
67. Monticelli, L. A. et al. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat. Immunol. 12, 1045-1054 (2011).
68. Bernink, J. H. et al. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat. Immunol. 14, 221-229 (2013).
69. Sonnenberg, G. F. et al. Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science 336, 1321-1325 (2012).
70. + T-cell responses to intestinal commensal bacteria. Nature 498, 113-117 (2013).
71. + group 1 and group 3 innate lymphoid cells in the intestinal lamina propria. Immunity 43, 146-160 (2015).
72. + innate lymphoid cells. Front. Immunol. 3, 72 (2012).
73. Hanash, A. M. et al. Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. Immunity 37, 339-350 (2012).
74. Aparicio-Domingo, P. et al. Type 3 innate lymphoid cells maintain intestinal epithelial stem cells after tissue damage. J. Exp. Med. 212, 1783-1791 (2015).
75. Mortha, A. et al. Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis. Science 343, 1249288 (2014).
76. + T cells. Science 348, 1031-1035 (2015).
77. + innate lymphoid cells. Nature 494, 261-265 (2013).
78. + RORyt- lymphoid cells. EMBO J. 30, 2934-2947 (2011).
79. Klose, C. S. N. et al. Differentiation of type 1 ILCs from a common progenitor to all helper-like innate lymphoid cell lineages. Cell 157, 340-356 (2014).
80. + ILC3s in models of intestinal inflammation. J. Exp. Med. 212, 1869-1882 (2015).
81. Rankin, L. C. et al. Complementarity and redundancy of IL-22-producing innate lymphoid cells. Nat. Immunol. 17, 179-186 (2016).
82. + innate lymphoid cells. Immunity 37, 674-684 (2012).
83. Geiger, T. L. et al. Nfil3 is crucial for development of innate lymphoid cells and host protection against intestinal pathogens. J. Exp. Med. 211, 1723-1731 (2014).
84. Abt, M. C. et al. Innate immune defenses mediated by two ILC subsets are critical for protection against acute clostridium difficile infection. Cell Host Microbe 18, 27-37 (2015).
85. Cua, D. J. & Tato, C. M. Innate IL-17-producing cells: the sentinels of the immune system. Nat. Rev Immunol. 10, 479-489 (2010).
86. Gladiator, A., Wangler, N., Trautwein-Weidner, K. & LeibundGut-Landmann, S. Cutting edge: IL-17-secreting innate lymphoid cells are essential for host defense against fungal infection. J. Immunol. 190, 521-525 (2013).
87. hi cells are multipotential "inflammatory" type 2 innate lymphoid cells. Nat. Immunol. 16, 161-169 (2015).
88. Oeser, K., Schwartz, C. & Voehringer, D. Conditional IL-4/IL-13-deficient mice reveal a critical role of innate immune cells for protective immunity against gastrointestinal helminths. Mucosal Immunol. 8, 672-682 (2015).
89. Spencer, S. P. et al. Adaptation of innate lymphoid cells to a micronutrient deficiency promotes type 2 barrier immunity. Science 343, 432-437 (2014).
90. Wilhelm, C. et al. Critical role of fatty acid metabolism in ILC2-mediated barrier protection during malnutrition and helminth infection. J. Exp. Med. 213, 1409-1418 (2016).
91. Peters, C. P., Mjösberg, J. M., Bernink, J. H. & Spits, H. Innate lymphoid cells in inflammatory bowel diseases. Immunol. Lett. 172, 124-131 (2016).
92. Geremia, A. et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J. Exp. Med. 208, 1127-1133 (2011).
93. Hueber, W. et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double- blind placebo-controlled trial. Gut 61, 1693-1700 (2012).
94. Lee, J. S. et al. Interleukin-23-Independent IL-17 production regulates intestinal epithelial permeability. Immunity 43, 727-738 (2015).
95. Fuchs, A. et al. Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-γ-producing cells. Immunity 38, 769-781 (2013).
96. +ILC subset in the inflamed terminal ileum of patients with Crohn's disease. Cell. Immunol. 304-305, 63-68 (2016).
97. + natural killer cells in the intestinal mucosa of patients with Crohn's disease. Gastroenterology 139, 882-892.e1-3 (2010).
98. + innate lymphocytes. Immunity 33, 736-751 (2010).
99. Lim, A. I. et al. IL-12 drives functional plasticity of human group 2 innate lymphoid cells. J. Exp. Med. 213, 569-583 (2016).
100. Lo, B. C. et al. The orphan nuclear receptor RORα and group 3 innate lymphoid cells drive fibrosis in a mouse model of Crohn's disease. Sci. Immunol. 1, eaaf8864 (2016).
101. Doherty, T. A. et al. Group 2 innate lymphocytes (ILC2) are enriched in active eosinophilic esophagitis. J. Allergy Clin. Immunol. 136, 792-794.e3 (2015).
102. Simon, D., Radonjic-Hösli, S., Straumann, A., Yousefi, S. & Simon, H.-U. Active eosinophilic esophagitis is characterized by epithelial barrier defects and eosinophil extracellular trap formation. Allergy 70, 443-452 (2015).
103. Dyring-Andersen, B. et al. Increased number and frequency of group 3 innate lymphoid cells in nonlesional psoriatic skin. Br. J. Dermatol. 170, 609-616 (2014).
104. + ILC3 in lesional skin and blood of psoriasis patients. J. Invest. Dermatol. 134, 2351-2360 (2014).
105. + ILC3 in psoriasis. J. Invest. Dermatol. 134, 984-991 (2014).
106. Roediger, B. et al. Cutaneous immunosurveillance and regulation of inflammation by group 2 innate lymphoid cells. Nat. Immunol. 14, 564-573 (2013).
107. Kim, B. S. et al. TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation. Sci. Transl. Med. 5, 170ra16 (2013).
108. Salimi, M. et al. A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J. Exp. Med. 210, 2939-2950 (2013).
109. Soumelis, V. et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat. Immunol. 3, 673-680 (2002).
110. Savinko, T. et al. IL-33 and ST2 in atopic dermatitis: expression profiles and modulation by triggering factors. J. Invest. Dermatol. 132, 1392-1400 (2012).
111. Wang, Y.-H. et al. IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells. J. Exp. Med. 204, 1837-1847 (2007).
112. Saunders, S. P. et al. Spontaneous atopic dermatitis is mediated by innate immunity, with the secondary lung inflammation of the atopic march requiring adaptive immunity. J. Allergy Clin. Immunol. 137, 482-491 (2016).
113. Chen, L.-Y. et al. Protein palmitoylation by ZDHHC13 protects skin against microbial-driven dermatitis. J. Invest. Dermatol. https://doi.org/10.1016/j.jid.2016.12.011 (2013).
114. Kim, B. S. et al. Basophils promote innate lymphoid cell responses in inflamed skin. J. Immunol. 193, 3717-3725 (2014).
115. Tang, A., Amagai, M., Granger, L. G., Stanley, J. R. & Udey, M. C. Adhesion of epidermal Langerhans cells to keratinocytes mediated by E-cadherin. Nature 361, 82-85 (1993).
116. Trautmann, A. et al. The differential fate of cadherins during T-cell-induced keratinocyte apoptosis leads to spongiosis in eczematous dermatitis. J. Invest. Dermatol. 117, 927-934 (2001).
117. Salimi, M. et al. Group 2 innate lymphoid cells express functional NKp30 receptor inducing type 2 cytokine production. J. Immunol. 196, 45-54 (2016).
118. Michalek, I. M., Loring, B. & John, S. M. A systematic review of worldwide epidemiology of psoriasis. J. Eur. Acad. Dermatol. Venereol 31, 205-212 (2017).
119. Bowcock, A. M. & Krueger, J. G. Getting under the skin: the immunogenetics of psoriasis. Nat. Rev Immunol. 5, 699-711 (2005).
120. Austin, L. M., Ozawa, M., Kikuchi, T, Walters, I. B. & Krueger, J. G. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-y, interleukin-2, and tumor necrosis factor-a, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J. Invest. Dermatol. 113, 752-759 (1999).
121. + innate lymphocytes and y5 T cells initiate psoriasiform plaque formation in mice. J. Clin. Invest. 122, 2252-2256 (2012).
122. + group 3 innate lymphoid cells to orchestrate normal skin repair. Nat. Commun. 7, 11394 (2016).
123. Rak, G. D. et al. IL-33-Dependent group 2 innate lymphoid cells promote cutaneous wound healing. J. Invest. Dermatol. 136, 487-496 (2016).
124. 2 constrains systemic inflammation through an innate lymphoid cell-IL-22 axis. Science 351, 1333-1338 (2016).
125. Dalli, J., Colas, R. A., Arnardottir, H. & Serhan, C. N. Vagal regulation of group 3 innate lymphoid cells and the immunoresolvent PCTR1 controls infection resolution. Immunity 46, 92-105 (2017).
126. Cols, M. et al. Expansion of inflammatory innate lymphoid cells in patients with common variable immune deficiency. J. Allergy Clin. Immunol. 137, 1206-12 15.e1-6 (2016).
127. + group 1 innate lymphoid cells (ILC) form a functionally distinct ILC subset that is increased in systemic sclerosis. J. Immunol. 196, 2051-2062 (2016).
128. De Lauretis, A. et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J. Rheumatol 40, 435-446 (2013).
129. Khanna, D. et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 387, 2630-2640 (2016).
130. Leijten, E. F. A. et al. Brief report: enrichment of activated group 3 innate lymphoid cells in psoriatic arthritis synovial fluid. Arthritis Rheumatol. 67, 2673-2678 (2015).
131. Triggianese, P. et al. Evidence of IL-17 producing innate lymphoid cells in peripheral blood from patients with enteropathic spondyloarthritis. Clin. Exp. Rheumatol 34, 1085-1093 (2016).
132. Rodríguez-Carrio, J. et al. Brief report: altered innate lymphoid cell subsets in human lymph node biopsy specimens obtained during the at-Risk and earliest phases of rheumatoid arthritis. Arthritis Rheumatol. 69, 70-76 (2017).
133. Lin, Y. C. et al. Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis. Ann. Clin. Transl Neurol. 2, 445-455 (2015).
134. Perry, J. S. A. et al. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Sci. Transl. Med. 4, 145ra106 (2012).
135. Gillard, G. O., Saenz, S. A., Huss, D. J. & Fontenot, J. D. Circulating innate lymphoid cells are unchanged in response to DAC HYP therapy J. Neuroimmunol. 294, 41-45 (2016).
136. Gross, C. C. et al. Distinct pattern of lesion distribution in multiple sclerosis is associated with different circulating T-helper and helper-like innate lymphoid cell subsets. Mult. Scler. 23, 1025-1030 (2016).
137. Gross, C. C. et al. Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm 3, e289 (2016).
138. Hatfield, J. K. & Brown, M. A. Group 3 innate lymphoid cells accumulate and exhibit disease-induced activation in the meninges in EAE. Cell Immunol. 297, 69-79 (2015).
139. Gadani, S. P., Smirnov, I., Smith, A. T., Overall, C. C. & Kipnis, J. Characterization of meningeal type 2 innate lymphocytes and their response to CNS injury. J. Exp. Med. 214, 285-296 (2017).
140. Neumann, K. et al. A proinflammatory role of type 2 innate lymphoid cells in murine immune-mediated hepatitis. J. Immunol. 198, 128-137 (2017).
141. McHedlidze, T et al. Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis. Immunity 39, 357-371 (2013).
142. Yang, Z., Tang T., Wei, X., Yang, S. & Tian, Z. Type 1 innate lymphoid cells contribute to the pathogenesis of chronic hepatitis B. Innate Immun. 21, 665-673 (2015).
143. Vély, F et al. Evidence of innate lymphoid cell redundancy in humans. Nat. Immunol. 17, 1291-1299 (2016).
144. Fischer, A. & Rausell, A. Primary immunodeficiencies suggest redundancy within the human immune system. Sci. Immunol. 1, eaah5861 (2016).